CSL Behring steps up Covid fight
Biotechnology giant CSL has stepped up the fight against Covid-19 with the announcement it has begun trials to evaluate its monoclonal antibody CSL312 for respiratory distress. The company’s CSL Behring arm has begin phase II placebo-controlled studies on the safety and efficacy of the garadacimab, Factor XIIa antagonist monoclonal antibody for patients with Covid-19 related…
Details










